Bli medlem
Bli medlem

Du är här

2015-04-13

MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab Program in Psoriatic Arthritis

MorphoSys AG / MorphoSys AG : MorphoSys to Receive Milestone Payment for
Guselkumab Program inPsoriatic Arthritis . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that its collaborator Janssen Biotech, Inc. (Janssen) has initiated a
phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody
guselkumab (CNTO1959). The event triggered a clinical milestone payment to
MorphoSys. Further financial details were not disclosed.

"We are delighted to see Janssen moving guselkumab into a new clinical program
for psoriatic arthritis," commented Dr. Marlies Sproll, Chief Scientific
Officer of MorphoSys AG. "Today's news marks the first of up to six clinical
milestone events we expect to see with partners this year."

MorphoSys's collaboration with Janssen has resulted in three clinical programs
to date, two of which are in phase 2 development and one, guselkumab, in
phase 3 in psoriasis (most advanced trial). In total, MorphoSys's partnered
and proprietary clinical pipeline currently comprises 23 unique antibody
molecules which are being evaluated in more than 60 clinical trials.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 90 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and
Ylanthia® and 100 billion high potentials® are registered trademarks of
MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Manager Corporate Communications&IR

Jessica Rush
Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF)
http://hugin.info/130295/R/1910171/681151.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1910171

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.